Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) based on results of a previous imaging procedure such as Computed Tomography (CT) or MRI, which should have been performed within 12 months prior to ICF signature.~Exclusion Criteria:~* Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent injection~* Patient presenting extra cranial lesions and/or extra-dural lesions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI (Type: OTHER): cross-over design. each patient will receive gadopiclenol for the first MRI and gadobutrol for the second MRI
- gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI (Type: OTHER): cross-over design. each patient will receive gadobutrol for the first MRI and gadopiclenol for the second MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).